We aim for sustainable performance over time to benefit patients, employees, shareholders and society. Solid financial results and maintaining the trust of society underpin our ability to create value.
Novartis Campus in Basel, Switzerland

Investor Update on Access & Sustainability


November 30, 2022
Basel, Switzerland
 

Watch the webcast

Download the presentation (PDF 1.6 MB)

 

Walkway at the entrance of the Novartis Campus in Basel, Switzerland

Investors Event Calendar


View recent presentations and learn more about upcoming events.


December 01, 2022
Société Générale Premium Review Conference
Paris, France
 

 


 

Doctor prescribing medication in Rwanda

Environmental, Social and Governance (ESG)


Novartis aims to hold itself to the highest standards of sustainability and ethical business practices. We take bold steps to increase access to medicines, tackle complex global health challenges, and do our part as a responsible corporate citizen.

ESG Updates: Oct 31, 2022 (PDF 0.5 MB) | July 20, 2022 (PDF 0.4 MB) | Apr 27, 2022 (PDF 0.7 MB) | Feb 03, 2022 (PDF 1.7 MB)
Latest updates: Novartis Enterprise Risk Management (PDF 0.2 MB)  | Materiality Assessment


We have created a set of environmental, social and governance indices to signpost where our key disclosures can be found across our publications and channels. Novartis aims to report comprehensively and transparently for all stakeholders concerned with ESG topics.

Stocks
Silvia Bally, a Novartis employee at a production facility in Stein, Switzerland

Novartis Annual Reporting Suite

Read and download our integrated report, annual regulatory filings, and other disclosures.

 

Pulse Updates

December 16, 2021

Novartis receives FDA Fast Track designation for branaplam (LMI070) for the treatment of Huntington’s Disease

Read More

September 28, 2021

FDA grants Priority Review for investigational targeted radioligand therapy 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer (mCRPC)

Read More

 

September 03, 2021

Novartis announces discontinuation of CIRRUS-1 study of CFZ533 (iscalimab) in kidney transplant patients

Read More

September 02, 2021

Novartis receives FDA fast track designation for LNA043 in osteoarthritis of the knee

Read More


Investor Relations Contacts

For questions about investor relations or the share registry, please contact our team.

 


Stay Up-to-Date

Stay connected to the latest news and information from Novartis

 

Novartis AG
Lichtstrasse 35
CH-4056 Basel, Switzerland